MAPK3 and small cell lung carcinoma: In SCLC cells derived from primary SCLC tumors, treatment with an ERBB2 inhibitor resulted in repression of phosphorylation of AKT and ERK1/2, indicating an inhibitory effect on AKT and ERK1/2 signaling (Fig. 4a).